Ophthalmology
We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.
We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes gene therapies and treatments for geographic atrophy (GA).
Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to redefine standards of care for retinal diseases.
Partnering opportunities we are looking for:
- Retinal diseases and long-acting ocular drug delivery solutions
- Glaucoma and dry eye disease
Example partnerships
AntlerA – Acquisition of Wnt targeting programs for potential best-in-class treatment for multiple indications including neovascular age-related macular degeneration and diabetic macular edema.
Character Biosciences – Research collaboration and license agreement to better understand the genomic factors that increase an individual's risk for developing ocular diseases.
ForSight VISION4 – Acquisition to acquire Susvimo™ for long-acting ocular delivery
Lineage Cell Therapeutic – Collaboration and license agreement for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).
Pieris Pharmaceuticals – Research collaboration and license agreement to discover, develop and commercialize locally delivered ophthalmology therapies.
SemaThera – Research collaboration targeting SEMA3A for diabetic retinopathy (DR)
Your dedicated partnering leads in Ophthalmology
Tom Zioncheck, Head of Neurology, Ophthalmology and Rare Diseases, Pharma Partnering
Rose Damestani, Search & Evaluation Lead Neurology, Ophthalmology & Rare Diseases, Pharma Partnering
